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Genetic Association of the Tachykinin
Receptor 1 TACR1 Gene in Bipolar
Disorder, Attention Deficit Hyperactivity
Disorder and the Alcohol Dependence
Syndrome.
Am J Med Genet Part B 165B:373–380.Single nucleotide polymorphisms (SNPs) in the tachykinin re-
ceptor 1 gene (TACR1) are nominally associated with bipolar
affective disorder (BPAD) in a genome-wide association study
and in several case-control samples of BPAD, alcohol depen-
dence syndrome (ADS) and attention-deficit hyperactivity dis-
order (ADHD). Eighteen TACR1 SNPs were associated with
BPADina sample (506 subjects) fromUniversityCollegeLondon
(UCL1), the most significant being rs3771829, previously asso-
ciated with ADHD. To further elucidate the role of TACR1 in
affective disorders, rs3771829 was genotyped in a second BPAD
sample of 593 subjects (UCL2), in 997 subjects with ADS, and
a subsample of 143 individuals diagnosed with BPAD and
comorbid alcohol dependence (BPALC). rs3771829 was associ-
ated with BPAD (UCL1 and UCL2 combined: P¼ 2.0 103),
ADS (P¼ 2.0 103) and BPALC (P¼ 6.0 104) compared
with controls screened for the absence of mental illness and
alcohol dependence. DNA sequencing in selected cases of BPAD
and ADHDwho had inherited TACR1-susceptibility haplotypes
identified 19 SNPs in the promoter region, 50UTR, exons, intron/
exon junctions and 30 UTR of TACR1 that could increase
vulnerability to BPAD, ADS, ADHD, and BPALC. Alternative
splicing of TACR1 excludes intron 4 and exon 5, giving rise to
two variants of the neurokinin 1 receptor (NK1R) that differ in
binding affinity of substance P by 10-fold. A mutation in intron
four, rs1106854, was associated with BPAD, although a regula-
tory role for rs1106854 is unclear. The association with TACR1
and BPAD, ADS, and ADHD suggests a sharedmolecular patho-
physiology between these affective disorders.
 2014 The Authors. American Journal of Medical Genetics Part B: Neuropsy-
chiatric Genetics Published by Wiley Periodicals.
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Bipolar affective disorder (BPAD) has a lifetime risk of up to 1.5%
[Merikangas et al., 2011]. The genes responsible for BPAD also
increase susceptibility to unipolar affective disorder, suicidality,
cyclothymia, and hypomania [Bertelsen et al., 1977]. Alcohol
dependence syndrome (ADS) is strongly comorbid with BPAD,
with 38–50% of bipolar cases also having a diagnosis of an alcohol
use disorder [Angst et al., 2006;Goldstein et al., 2006]. In one study,
up to 36% of patients with BPAD had a positive family history
of alcohol dependence among first-degree relatives [Mantere
et al., 2012]. There is also a strong relationship between adolescent
attention deficit hyperactivity disorder (ADHD) and adult alcohol
dependence [Edwards and Kendler, 2012] with at least 30% of
subjects with ADHD reported to develop an alcohol use disorder
[Wilens et al., 2011; Tuithof et al., 2012].
Previous genetic studies of bipolar and unipolar affective disor-
der comorbid alcohol dependence show replicated significant
linkage in multiply affected alcoholism families [Dick et al.,
2002; Lappalainen et al., 2004; Guerrini et al., 2005]. A genome
wide association study (GWAS) of combined alcohol dependence
syndrome and bipolar disorder, BPALC, implicated several genes,
CDH11, COL11A2, NMUR2, XPO7, and SEMA5A, which had
previously been shown to be associated with ADS [Lydall et al.,
2011]. Several genes such as CDH13, CSMD2, GRID1, andHTR1B
were implicated in susceptibility to unipolar depression comorbid
with alcohol dependence [Edwards et al., 2012]. Ten SNPs in the
tachykinin receptor 1 (TACR1) gene were nominally associated
with BPALC, including the intronic marker, rs3771829 (P¼ 3.0
 103) [Lydall et al., 2011]. The TACR1 gene is located on
chromosome 2 and encodes the neurokinin 1 receptor which
primarily binds the tachykinin, substance P. These tachykinin
receptors are G-protein coupled receptors containing seven hydro-
phobic transmembrane spanning regions [Maggi, 1995]. A synon-
ymous SNP in exon 1 of TACR1, rs6715729, has been associated
with ADS compared with screened controls in a Caucasian popu-
lation (P¼ 0.0006, odds ratio (OR)¼ 6.13, 95% confidence inter-
vals (CI)¼ 4.06–9.23). The authors also report two risk haplotypes
for ADS in the 50 end of TACR1, formed by the three-SNP
combinations of rs6715729-rs735668-rs6741029 [Seneviratne
et al., 2009]. More recently, five 30 and 50 TACR1 SNPs,
rs3771863, rs3755459, rs10490308, rs11688000, and one SNP in
a stop codon, rs1106855, were significantly related to ADS severity
[Blaine et al., 2013]. Functional magnetic resonance imaging
(fMRI) responses to alcohol cues showed three of these genetic
markers, whichmay affectTACR1 transcription and/or translation,
were associated with brain regions in the mesocorticolimbic path-
way [Blaine et al., 2013].
Neurokinin 1 receptors (NK1R) encoded by TACR1 are highly
expressed in brain regions associated with reward and reinforce-
ment.Thebindingdensity ofNK1R ishighest in the locus coeruleus,
which is important for mood regulation and response to stress
[Caberlotto et al., 2003]. Mice with functional ablation of NK1R
(Nk1r/) have significantly reduced ethanol intake while acute
blockade of NK1Rs in wild type mice mimics this effect on alcohol
consumption. Inactivation of NK1Rs critically modulates alcohol
reward and escalation, supporting a direct role of NK1R in theregulation of alcohol intake [Thorsell et al., 2010], further impli-
cating NK1R function in the development of alcohol dependence.
The effects ofNK1Rantagonismonalcohol anddrug reward appear
to be selective [Thorsell et al., 2010], involving dopaminergic
pathways from the ventral tegmental area of the midbrain to
the cerebral cortex and also ascending serotonergic pathways
[Commons, 2009]. However, the direct effect of NK1R on meso-
limbic dopaminergic signalling remains unclear [Rupniak and
Jackson, 1994]. Furthermore, Nk1r/ mice are hyperactive and
have an atypical response to psychostimulants. They also express
greater impulsivity and inattentiveness than wild types in the
5-Choice Serial Reaction-Time Task and are proposed as a model
for ADHD [Yan et al., 2009].
Todate, allelic associationshave been foundbetweenfiveTACR1
SNPs and BPAD in family-based association studies [Perlis
et al., 2008] and several GWAS studies [Ferreira et al., 2008; Sklar
et al., 2008]. Within 50 kb of TACR1, 18 SNPs out of a total of 80
were significantly associated with BPAD in the UCL1 sample of 506
BPAD subjects, with rs3771829 showing the strongest association
(P¼ 2.5 103). A further 10 SNPs were associated with BPAD in
the Systematic Treatment Enhancement Protocol for Bipolar Dis-
order (STEP-BD) and Wellcome Trust Case Control Consortium
(WTCCC) samples. When all three samples were combined, seven
SNPs were associated with BPAD [Ferreira et al., 2008; Sklar
et al., 2008]. The pattern of these SNPs differed in each sample
suggesting allelic and haplotypic heterogeneity in disease suscepti-
bility. None of the TACR1 SNPs were associated with BPAD at the
level of genome-wide significance in any one sample although the
combined evidence supported the TACR1 association with BPAD.
The top Psychiatric Genetics Consortium (PGC) SNP forADHD in
TACR1, located approximately 5 kb downstream, is rs4614953
[Neale et al., 2010], close to the PGC BPAD associated marker,
rs2422090 [Sklar et al., 2011]. Linkage disequilibrium (LD) analysis
shows that these SNPs are inLD in theEuropean samples of the 1000
genomes project [1000 Genomes Project Consortium, 2010], with
an r2 of 1.0. Four TACR1 SNPs, including the top two UCL BPAD
SNPs, rs3771829 and rs3771833, which are in LDwith one another,
were associated with ADHD (P¼ 0.01–0.00008) [Yan et al., 2010].
The two UCL BPAD TACR1 markers are not in LD with the PGC
ADHD and BPAD SNPs, rs4614953 and rs2422090, or the SNP,
rs6715729, associated with ADS (data not shown), suggesting
that independent genetic risk factors in TACR1 predict affective
disorder phenotypes. The aim of this study is to further investigate
the association of TACR1 with BPAD, BPALC, ADS, and ADHD.METHODS
UCL Clinical Sampling
The UCL BPAD cohort consists of 1,099 individuals. These were
sampled in two cohorts. The first cohort (UCL1) comprised 506
bipolar I cases [Ferreira et al., 2008; Sklar et al., 2008] while the
second cohort (UCL2) comprised 409 bipolar I (69%) and 184
bipolar II cases [Dedman et al., 2012]. Among the UCL1 BPAD
cases were 143 with comorbid ADS according to Research Diag-
nostic Criteria (RDC) [Lydall et al., 2011]. All UCL bipolar cases
were interviewed by a psychiatrist using the lifetime version of the
SHARP ET AL. 375Schedule for Affective Disorders and Schizophrenia-Lifetime Ver-
sion (SADS-L) schedule18 [Spitzer and Endicott, 1977], rated with
the 90-item Operational Criteria Checklist (OPCRIT) [McGuffin
et al., 1991] and met diagnostic criteria for bipolar disorder
according to RDC [Spitzer et al., 1978]. The UCL ADS sample
comprised 997 ADS cases, recruited as part of the UK-COGA
(United KingdomCollaborative Study on the Genetics of Alcohol-
ism) study, were diagnosed using a version of the SSAGA-II
questionnaire modified for the UK [Bucholz et al., 1994] and
met diagnostic criteria according to DSM-IV and ICD-10. ADS
cases were also rated with the OPCRIT. Thirty-five cases of ADHD,
diagnosed by experienced clinicians using DSM-IV criteria from
two samples, one collected at Cardiff University and the second
fromthe InstituteofPsychiatry, London [Yanet al., 2010]wereused
for DNA sequencing.
The sample of 1,056 normal controls comprised 672 screened
controls who were interviewed with the initial clinical screening
questions of the SADS-L and selected on the basis of not having a
family history of schizophrenia, alcohol dependence or BPAD, for
having no past or present personal history of any RDC-defined
mental disorder, and were not heavy drinkers; plus 384 unscreened
British normal volunteers provided by European Collection of
AnimalCell Cultures (ECACC).All cases and controlswere selected
to be of UK or Irish ancestry as described previously [Datta
et al., 2010]. UK National Health Service multicenter and local
research ethics approvals were obtained and signed informed
consent was given by all subjects. Genomic DNA was obtained
from frozen whole blood samples for cases and controls in UCL1
and from saliva samples for the cases in UCL2. DNA was extracted
for all samplesusingmethodswehavepublishedpreviously [Pereira
et al., 2011] and quantified with PicoGreen (Invitrogen, Paisley,
UK) by fluorimetry.
Sequencing
A total of 32 BPALC subjects from the UCL1 BPAD cohort along
with 35 cases of ADHD and a further 32 random normal compari-
son subjects from the control samplewere selected for sequencing, if
they had inherited a TACR1 susceptibility haplotype, based on the
criteria of whether an individual was homozygous or heterozygous
for the two GWAS TACR1 SNP markers rs3771829 and rs3771833
alleles. Sequencing was carried out on the promoter region, 1000
base pairs upstream of the transcriptional start site, 50 untranslated
region (UTR), the exons, intron/exon junctions and the entire 3’
UTR of TACR1 isoform 1 (NM_001058.3) which contains all five
exons (Table SI). Sequencing was done using the Big Dye termina-
tor v3.1 Cycle Sequencing kit (Applied Biosystems, Warrington,
UK) on an ABI 3730xl DNA Analyzer (Applied Biosystems).
Sequencing data were analysed using the Staden Package
[Staden, 1996].
Genotyping and Association Analysis
To determine whether TACR1 increases susceptibility to affective
disorders, KBiosciences allele-specific PCR (KASPar) (LGC Geno-
mics KBioscience, Hoddesdon, UK) or TaqMan (Applied Biosys-
tems) genotyping assays were designed. The top two TACR1UCL1
BPAD GWAS SNPs, rs3771829 and rs3771833, and two SNPs,rs3771856 and rs17011370, also associated with ADHD [Yan
et al., 2009], were KASPar genotyped on a LightCycler 480 Real-
Time PCR System (Roche, Burgess Hill, UK) in UCL1 and UCL2
BPAD and ADS samples, and screened and unscreened controls.
Where TACR1 nucleotide changes were detected by sequencing the
ADHD and BPALC cases, KASPar genotyping was then performed
in the UCL1 and UCL2 BPAD samples and controls. Rare variants,
potentially aetiological SNPs or SNPs associated with BPAD were
genotyped using KASPar in the UCL ADS samples. One SNP,
rs1106854, is a triallelic base, therefore two KASPar genotyping
assays were carried out, one for each of the minor alleles. For one
SNP, rs13387833, aKASPar assay couldnot be successfully designed
and a TaqMan genotyping assay (Applied Biosystems) was carried
out in all cases and controls. Quality control to confirm the
reproducibility of genotypeswas performed as describedpreviously
[Dedman et al., 2012]. All these data were analysed to confirm
Hardy–Weinberg equilibrium (HWE). Genotypic and allelic asso-
ciations for SNPs were tested using Fisher’s exact, x2 or Cochrane
trend tests. Significance values shown for all analyses are un-
corrected for multiple testing and a cut-off significance value of
P< 0.05 was used.
Bioinformatic analysis to determine potentially functional SNPs
was carried out using the UCSC genome browser (http://genome.
ucsc.edu/), Transcription Element Search System (TESS)
[Schug, 2008], Codon Plot (http://www.bioinformatics.org/
sms2/codon_plot.html), exonic splicing enhancerprediction server
RESCUE-ESE [Fairbrother et al., 2002], Alternative Splice Site
Predictor (ASSP) [Wang and Marin, 2006], and MicroInspector
(http://bioinfo.uni-plovdiv.bg/microinspector/). 1000 genomes
data [1000 Genomes Project Consortium, 2010] was downloaded
and imputation analysis was performed using IMPUTE2 [Howie
et al., 2009, 2011] and SNPTEST version 2.0 using the frequentist
association test [Marchini andHowie, 2010]. The Ensembl Variant
Effect Predictor (VEP) [McLaren et al., 2010] was used to predict
the functional consequences of known and unknown variants and
regulatory region variants were analysed in the ENCODE data
[ENCODE Project Consortium, 2011].
RESULTS
TACR1 Association Analysis
In order to investigate whether TACR1 increases susceptibility to
affective disorders we analysed the effect of the top twoUCLGWAS
SNPmarkers, rs3771829 and rs3771833, in the combinedUCL1and
UCL2 sample of BPAD (Table I). Genotype data did show signifi-
cant association with BPAD in comparison with screened controls
with a confirmed negative history of bipolar disorder and alcohol
dependence (rs3771829: P¼ 0.002, OR 1.57, CI 1.18–2.08;
rs3771833: P¼ 0.004, OR 1.43, CI 1.12–1.83) but not relative to
unscreened controls (Table I). Neither SNP was associated with
BPAD in the UCL2 sample alone (data not shown) but both SNPs
were associated inUCL1alone aswell as in combinationwithUCL2.
As reported previously [Lydall et al., 2011], one of these SNPs was
associated with the sub-group of BPALC cases compared with
screened controls (rs3771829: P¼ 0.005, OR 1.87, CI 1.20–2.92)
(Table I). Since the association with BPAD may be driven by the
subsample of patients with comorbid ADS, the BPALC subgroup
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376 AMERICAN JOURNAL OF MEDICAL GENETICS PART Bwas removed from the UCL1 BPAD analysis. A significant associa-
tionwas still observed between BPADand rs3771829 (P¼ 0.01, OR
1.58,CI1.11–2.24) and rs3771833 (P¼ 0.04,OR1.39,CI1.02–1.90)
(Table SII). When we genotyped these SNPs in the UCL ADS
sample, rs3771829 was associated with ADS when compared with
the screened controls (P¼ 0.002, OR 1.56, CI 1.17–2.09) (Table I).
Furthermore, when the UCL BPAD and ADS samples were com-
bined, there was an enhanced significant association with both
rs3771829 and rs3771833 when compared with screened controls
(P¼ 0.0009, OR 1.57, CI 1.20–2.04; P¼ 0.009, OR 1.36, CI 1.08–
1.71, respectively). Since, wewere unable to confirm the association
between TACR1 and BPAD, BPALC or ADS with our unscreened
controls all subsequent case control analysis has been carried out
using the screened control sample.
Detection and Evaluation of Other Variants in
TACR1
A total of 19 SNPs were detected by sequence analysis across the
promoter region, 50UTR, exons, intron/exon junctions and 30UTR
ofTACR1, of which one was novel (Table SIII). These included one
synonymous coding base pair change, rs6715729; nine promoter
SNPs: rs59099335, rs34374747, rs1477157, rs1477156, rs13387833,
rs2111375, rs2193405, rs13384011, and rs10210648; one SNP in the
exon 1 50 UTR, rs200655774; five intronic SNPs: one in intron 1,
rs2024512, one in intron 3, rs78052302, and three in intron 4,
rs201914096, rs1106854, and rs1106855 (not genotyped); and five
SNPs in the 30 UTR of exon 5: rs881, ss825678898, rs17010664,
rs62148938, and rs12713828.
Bioinformatic analysis of the promoter region SNPs for altered
transcription factor binding sites indicated that the mutant alleles
of all promoter and 5-UTR SNPs are likely to both introduce new
transcription factor binding sites and prevent binding of some
transcription factors compared to their respective common alleles
(TESS). The Mfold program showed that the 50 UTR rs200655774
base pair change is unlikely to significantly alter the secondary
structure of TACR1 mRNA. The minor allele of the exon 1
synonymous SNP, rs6715729, results in a modest reduction in
codon usage (Phe TTT 57% >Phe TTC 43% frequency, Codon
Plot) but is not predicted to be an exonic splicing enhancer
(RESCUE-ESE). The five 3-UTR SNPs are all predicted to gain
and/or lose miRNA binding sites (MicroInspector). One intronic
SNP, rs201914096, is predicted to introduce an alternative iso-
form/cryptic splice site acceptor with a splice site strength of 5.676,
which has a greater than 95% likelihoodof being a functional splice
site (ASSP) [Wang and Marin, 2006]. The only SNP found by
sequencing to be associated in the combined UCL1 and UCL2
BPAD sample compared to screened controls (Table SIII), the
intronic triallelic base rs1106854, does not alter a splice site (ASSP).
An additional SNP, rs17011370, previously associatedwithADHD
[Yan et al., 2010] is nominally associated with the BPALC clinical
subgroup (Table SIV). Six SNPs were genotyped in ADS because
they had either been associated with ADHD previously [Yan
et al., 2010], or there was an increased frequency in sequenced
cases compared to sequenced controls, or based on predicted
functional effects. None of these were associated with ADS
(Table SV).
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Unscreened Controls
Significant differences in allele frequencies were observed between
the screened and unscreened controls (Table SVI). In particular,
the rs3771829 allele frequency was significantly different between
screened and unscreened controls (P¼ 0.003, OR 1.67, CI 1.19–
2.36). It is interesting that the unscreened controls have similar
allele frequencies to those of the 1000 genome controls and the
WTCCC controls (data not shown).Imputed Tests of Association in TACR1 in
Bipolar Disorder and in Comborbid Bipolar
Alcohol Dependence
Imputation analysis using IMPUTE2 and SNPTEST predicted that
several regulatory region SNPs, as well as variants located both
upstream, downstream and in introns of TACR1 are significantly
associated in the UCL1 and UCL2 BPAD samples (Table SVII) and
in theBPALC subgroup (Table SVIII). Two synonymousvariants in
TACR1 were imputed to be associated with BPALC. In exon 5,
rs34117315 results in a modest reduction in codon usage (Ser TCG
15%> SerTCA13% frequency,CodonPlot). The second variant in
exon 3, chr2:75280825, also reduces codon usage (Ser TAT 58%>
Ser TAC 42%, Codon Plot). Neither variant was predicted to be an
exonic splicing enhancer (RESCUE-ESE). Several imputed regula-
tory region variants were predicted to be in regions showing
enrichment for theH3K27Ac histonemark,which is the acetylation
of lysine 27 of the H3 histone protein, often found near active
regulatory elements (ENCODE).DISCUSSION
Genetic association with TACR1 and BPAD was not found in the
UCL2 replication cohort for the markers most strongly associated
in the UCL1 GWAS sample [Sklar et al., 2008]. This result is
common in the field of complex genetic diseases reflecting both
the heterogeneity for bipolar disorder susceptibility genes, even
within a single ancestrally selected group of cases and controls, and
the presence of low frequency disease alleles. The association with
the top two GWAS hits held when the UCL1 and UCL2 BPAD
samples were combined. We also report replicated significant
associationwith intron 1TACR1mutations in BPAD in the BPALC
subgroup andADS cases in comparisonwith a screened population
of controls.
Sequencing of TACR1 in BPALC and ADHD cases detected one
novel base pair change in the 30 UTR, although this was not
significantly associated with BPAD when compared to screened
controls. Genotyping of an additional 18 database SNPs found by
sequencing TACR1 identified only one marker, rs1106854, posi-
tively associated with BPAD. Any possible regulatory role for this
intron 4 variant is unclear. The TACR1 gene is alternatively spliced
to exclude intron 4 and exon 5 of the gene, which gives rise to two
naturally occurring variants of NK1R. Truncated NK1R lacks 96
amino acid residues corresponding to the C-terminus of the full
length receptor. Furthermore, activation of full length and trun-cated NK1R results in differential receptor signalling mediated by
different G-proteins [Tuluc et al., 2009] and the truncated formhas
a 10-fold lower binding affinity to substance P than the long form
[Fong et al., 1992]. The longNK1R isoform is prevalent throughout
the human brain, while the truncated form is more common in
peripheral tissues, but to date there is little evidence for a region-
specific role for the two isoforms in the CNS [Caberlotto
et al., 2003]. Other regions of the TACR1 gene still need to be
screened for mutations: for example, the whole of intron 4 and
splice sites responsible for the alternative splicing ofTACR1.Wedid
not identify any other splice site SNPs that would result in differ-
ential expression of the two TACR1 isoforms in intron 4 in UCL1
andUCL2BPADcases, but the associationwith rs1106854warrants
further investigation. From the BPALC sub-analysis, there was
significant association with the intergenic SNP, rs17011370 located
approximately 270 kb upstream of TACR1.
The association between intronic loci in both BPAD and ADS
relative to screened controls supports previous evidence of associ-
ation in ADHD and further implicates a role for TACR1 as both a
functional and positional candidate gene with the potential to
increase susceptibility to alcohol dependence and affective disor-
ders. We did not find a significant association with controls who
had not been screened for a history of mental illness or drinking
behavior. These data highlight the importance of using the appro-
priate control group and to know the level of drinking in a control
population, as well as family histories of psychiatric diagnoses, for
true genetic associations tobe assessed [Nelson et al., 2013]. It is also
possible that the differences we observe between ADS cases and
controls are due to population stratification. While there was a
significant difference between BPAD in the absence of comorbid
alcohol dependence and screened controls for the two top GWAS
hits, the associationwasmuch stronger in theBPALCsubset relative
to screened controls. Thus, it is likely to be the comorbid ADS
present in a subsample of the BPAD cohort that is driving the
association we observe with BPAD and not the absence of drinking
behavior in the screened controls. Our data provide further evi-
dence of an association between TACR1 and ADS as found previ-
ously [Seneviratne et al., 2009].We did not replicate the significant
association with rs6715729 reported by Seneviratne et al. [2009] in
the UCL ADS sample, but a more recent study highlighted several
other TACR1 variants that predict fMRI responses to alcohol cues
and alcohol dependence [Blaine et al., 2013]. From our imputation
analysis, only two of the five SNPs reported in the study by Blaine
et al. [2013] were imputed from our data, but neither SNP was
significantly associated with either BPAD or BPALC.
The NK1R is an attractive molecular target for the treatment of
depression and anxiety [Ebner et al., 2009]. Previous in vivo studies
show thatNk1r/mice display increased alcohol drinking behav-
ior [Thorsell et al., 2010] and NK1R antagonist treatment signifi-
cantly inhibits operant self-administration of 10% ethanol
compared with vehicle in rats [Steensland et al., 2010; Schank
et al., 2013]. Interestingly, a SNP upstream of TACR1 present in
alcohol-preferring rats increased transcription factor binding, gene
transcription, alcohol self-administration and sensitivity to the
NK1R antagonist L822429 [Schank et al., 2013]. In a randomized
controlled study in recently detoxified in-patients with ADS, the
NK1R antagonist, LY686017, suppressed alcohol cravings. Brain
378 AMERICAN JOURNAL OF MEDICAL GENETICS PART BfMRI responses to affective stimuli likewise suggested beneficial
effects for the treatment of ADS [George et al., 2008]. The early
results in treating affective disorder with the NK1R antagonist
aprepitant were promising, but no effect was found in a controlled
treatment trial of depression [Hafizi et al., 2007; McCabe
et al., 2009; Chandra et al., 2010]. It is possible that only a small
genetic subgroup of ADS, ADHD and BPAD cases would benefit
from aprepitant, which points to a personalised targeting of this
drug based on genetic findings. So far the intronic SNP rs3771829
shows the greatest promise as a biomarker for prediction of
treatment effects from NK1R antagonists.
Taking our results together, we conclude that polymorphisms in
TACR1 significantly increase susceptibility toBPAD,ADS, aswell as
ADHD. The significant TACR1 allele frequency difference between
our screened and unscreened controls also suggests an effect from
TACR1 on normal drinking behavior. Additional studies are need-
ed to replicate these results in other samples with access to screened
and unscreened controls and to elucidate the regulatory
mechanism(s) by which these polymorphisms affect NK1R func-
tion in the brain.ACKNOWLEDGMENTS
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